ADC trials are moving from binary antigen testing to quantitative, multiparameter biomarker models that better predict efficacy and toxicity.
|Articles|July 17, 2019
Catalent Breaks Ground at $112-Million Drug Product Manufacturing Facility
Author(s)BioPharm International Editors
Catalent recently held a groundbreaking ceremony at its Bloomington, Indiana pharmaceutical fill/finish site.
Advertisement
Catalent recently held a ground breaking ceremony at its Bloomington, Indiana site to mark the start of construction on a $112-million drug product manufacturing facility, which will increase fill/finish capacity at the site by 79,000 ft2. The facility will house a high-speed vial line, using both ready-to-use components and bulk filling; a high-speed flexible syringe/cartridge line; a fully automated vial inspection machine; and all associated services and support areas. Catalent Biologics plans to create up to 200 new jobs to support the increased production. Completion of both construction and recruitment are expected by the end of 2024.
Source:
Advertisement
Related to this article
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
Advertisement
Advertisement
Trending on BioPharm International
1
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
2
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
3
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
4
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
5